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the antitumor efficacy of anti-GITR and
anti-PD-1 antibodies via an antigen
presenting independent mechanism
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Abstract
Background: TNF receptor family agonists and checkpoint blockade combination therapies lead to minimal tumor
clearance of poorly immunogenic tumors. Therefore, a need to enhance the efficacy of this combination therapy
arises. Antigen-presenting cells (APCs) present antigen to T cells and steer the immune response through
chemokine and cytokine secretion. DRibbles (DR) are tumor-derived autophagosomes containing tumor antigens
and innate inflammatory adjuvants.
Methods: Using preclinical murine lung and pancreatic cancer models, we assessed the triple combination therapy
of GITR agonist and PD-1 blocking antibodies with peritumoral injections of DRibbles-pulsed-bone marrow cells
(BMCs), which consisted mainly of APCs, or CD103+ cross-presenting dendritic cells (DCs). Immune responses were
assessed by flow cytometry. FTY720 was used to prevent T-cell egress from lymph nodes to assess lymph node
involvement, and MHC-mismatched-BMCs were used to assess the necessity of antigen presentation by the
peritumorally-injected DR-APCs.
Results: Tritherapy increased survival and cures in tumor-bearing mice compared to combined antibody therapy or
peritumoral DR-BMCs alone. Peritumorally-injected BMCs remained within the tumor for at least 14 days and
tritherapy efficacy was dependent on both CD4+ and CD8+ T cells. Although the overall percent of tumor-
infiltrating T cells remained similar, tritherapy increased the ratio of effector CD4+ T cells-to-regulatory T cells, CD4+
T-cell cytokine production and proliferation, and CD8+ T-cell cytolytic activity in the tumor. Despite tritherapy-
induced T-cell activation and cytolytic activity in lymph nodes, this T-cell activation was not required for tumor
regression and enhanced survival. Replacement of DR-BMCs with DR-pulsed-DCs in the tritherapy led to similar
antitumor effects, whereas replacement with DRibbles was less effective but delayed tumor growth. Interestingly,
peritumoral administration of DR-pulsed MHC-mismatched-APCs in the tritherapy led to similar antitumor effects as
MHC-matched-APCs, indicating that the observed enhanced antitumor effect was mediated independently of
antigen presentation by the administered APCs.
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Conclusions: Overall, these results demonstrate that peritumoral DR-pulsed-BMC/DC administration synergizes with
GITR agonist and PD-1 blockade to locally modulate and sustain tumor effector T-cell responses independently of T
cell priming and perhaps through innate inflammatory modulations mediated by the DRibbles adjuvant. We offer a
unique approach to modify the tumor microenvironment to benefit T-cell-targeted immunotherapies.
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Background
Peripheral administration of checkpoint inhibitors against
PD-1 and CTLA-4 are beneficial against a subset of
patients of most cancer types, yet fail to show responses in
all patients, primarily due to low tumor mutation burden
and pre-existing immunity. To further boost antitumor T-
cell responses, multiple combination strategies have been
tested in preclinical animal models and clinical trials. One
method combines agonist antibodies against TNF receptor
(TNFR) family members with checkpoint blockade [1–4],
such as targeting GITR and blocking PD-1 together. GITR
agonist increases activation, proliferation and effector
function of CD8+ and CD4+ T cells [5–7], while decreas-
ing intra-tumor regulatory T cells (Tregs) by depletion [8,
9] and Treg lineage stability alterations [10, 11], thus prov-
ing effective in various preclinical tumor models [7, 12,
13]. Recent studies combining anti-GITR and anti-PD-1
antibodies led to the rescue of dysfunctional/exhausted
CD8+ T cells [14, 15], and increased tumor infiltration of
effector and memory T cells with decreased Tregs and
myeloid derived suppressor cells (MDSCs) [2, 4, 16].
Although combined anti-GITR and anti-PD-1 antibody
therapy delayed tumor growth in murine tumor models
compared to single antibody administration, minimal
clearance of tumors was detected without using an
additional immune activating component, such as chemo-
therapy, vaccination or radiation, early during treatment
[2, 4, 16]. This minimal clearance was presumably due to
the inadequate ability of tumor-infiltrating T cells to ex-
pand and sustain effector function against local immune
suppression within the tumor. Although chemotherapy
and radiation therapy increases tumor antigenicity and
removes immunosuppressive cells from the tumor micro-
environment (TME) [17], toxic side effects arise. A safer
method to modulate the immunosuppressive TME to an
immune-stimulating one that sustains T-cell function will
prove to be beneficial.
Antigen presenting cells (APCs) present antigen, pro-
vide costimulation, and secrete chemokines/cytokines to
steer and control the direction of the immune response.
Direct peritumoral/intratumoral dendritic cell (DC) in-
jections are more beneficial than subcutaneous adminis-
tration [18], due to increased pro-immune cytokine
production and tumor CD8+ T-cell infiltration, along
with decreased Treg infiltration, tumor cell proliferation
via TNF-α [19] and immunosuppressive cytokines [20].
DRibbles are tumor-derived autophagosomes that con-
tain tumor proteins and peptides [21–23]. Long-lived
peptides, usually degraded by lysosomes, and short-lived
peptides that are quickly ubiquitinated and degraded by
proteasomes are both present within DRibbles [21, 24].
In addition, DRibbles contain many damage associated
molecular patterns (DAMPs) that act as danger signals
and induce innate inflammatory responses [21, 23, 25].
Therefore, upon uptake by APCs, DRibbles can provide
antigen as well as inflammatory danger signals. Given
the robust peripheral immune activation but lack of sus-
tained tumor effector T cells seen with TNFR agonist
and checkpoint blockade, we hypothesize that GITR
agonist and PD-1 blockade antibody therapy can be
benefited by the additional administration of peritumoral
DRibbles-pulsed-APCs that can modulate the local TME
towards an immune-stimulating environment.
Home to both the common myeloid and lymphoid
progenitor cells, the bone marrow gives rise to a variety
of immune cells, including APCs. Herein, we present
that the efficacy of systemically administered GITR
agonist and PD-1 blockade is enhanced by peritumoral
delivery of DRibbles-pulsed-bone marrow cells (BMCs)
or DCs. This study proposes that peritumoral DR-
pulsed-APC delivery following systemic T-cell targeted
therapies, can sensitize the local TME to create a sup-
portive environment that sustains T-cell immunity, inde-




6–8 week old BALB/c or C57BL/6 mice were purchased
from Jackson Laboratories. All experiments were con-
ducted in accordance with Earle A. Chiles Research Insti-
tute (EACRI) approved Institutional Animal Care and Use
Committee (IACUC) protocols.
DRibbles preparation
DRibbles were prepared as previously described [26].
Line-1 or Panc02 tumor cell lines were treated with 100
nmol/L bortezomib and 10 mmol/L NH4Cl for 18 h.
Autophagosomes were released via vigorous pipetting in
wash buffer (PBS 5mM EDTA, 20mM NH4Cl), and
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centrifuged at 1000 rpm for 7 min. Supernatant contain-
ing DRibbles was washed three times by centrifuging at
7500 rpm for 15 min at 4 °C. The resulting DRibbles pel-
let was aliquoted in 6% hetastarch and stored at − 80 °C
until use.
Cells and antibodies
Line-1 cells, a gift from Dr. Anderson (University of
Louisville School of Medicine, Microbiology and Im-
munology), was derived from a spontaneous BALB/c
lung tumor [27]. Received Line-1 cells were passaged
through a BALB/c mouse. The subcutaneous tumor was
harvested, cultured for 4 days, and aliquots were frozen.
Murine Panc02 and Panc02-SIY pancreatic cancer cells
(gifted by Dr. Gough, EACRI) were thawed and
expanded to generate a large cell bank. All cells were
cultured in RPMI 1640, 10% fetal bovine serum (FBS)
and 50 μg/ml gentamicin. For each experiment, frozen
cell aliquots were thawed and cultured for 2–3 days be-
fore tumor inoculation.
Bone marrow cells were isolated from femurs and tib-
ias of naïve mice. Red blood cells were lysed using ACK
lysis buffer (Life Technologies) and cells were plated in
petri dishes at a concentration of 2 × 106 cells/ml in
complete media (CM; RPMI 1640, 10% FBS, 50 μg/ml
gentamicin, 1:1000 β-mercaptoethanol) for 8–9 days.
Dendritic cells were generated from bone marrow cells
as described previously [28].
The agonist anti-GITR antibody (Clone DTA-1 – gifted
by Dr. S. Sakaguchi, Kyoto University, Kyoto, Japan), anti-
PD-1 antibody (Clone G4 – a gifted by Dr. C. Drake, Johns
Hopkins University), anti-CD4 antibody (Clone GK1.5)
and anti-CD8 antibody (Clone YTS 169.4) were purified
from hybridoma supernatant using a Protein G affinity
column. Antibody endotoxin levels were tested using Tox-
inSensor™ Chromogenic LAL (GenScript) to ensure low
levels.
Tumor challenge and treatment
BALB/c and C57BL/6 mice were injected subcutaneously
with 2 × 105 Line-1 or Panc02 cells, respectively, by the
right hind leg. 200 μg rat-anti-GITR antibody (Ab) was
intraperitoneally (i.p.) administered on day 5 and 8.
200 μg hamster-anti-PD-1 Ab was i.p administered on
days 10, 12 and 14. On day 12, 2 × 106 DR-pulsed BMCs
or DCs was injected peritumorally (p.t.) in 40 μL PBS.
Mice were randomized before starting antibody injec-
tions and antibody-treated mice were randomized before
p.t. injections. Mice with tumors greater than 150 mm2
were sacrificed according to IACUC guidelines.
Flow cytometry analysis of tissue infiltrating cells
Tumors, lymph nodes (LNs) and spleens were mechan-
ically dissociated. RBCs were lysed from splenocytes
using ACK lysis buffer. Minced tumors were shaken at
37 °C in CM containing 1mg/ml Collagenase IV
(Worthington Biochemical) and 10 μg/ml F68 for 1 h
and dissociated using a GentleMACS Dissociator. Flow
cytometry staining was performed on single cell suspen-
sions (Additional file 1: Table S1). Samples were run on
either BD LSRII or BD LSRFortessa.
Statistical analysis
GraphPad Prism 7.01 was used to perform statistical
tests. Kaplan-Meier survival curves were assessed using
the Log-rank Mantel-Cox test. One-way ANOVA with
Tukey’s multiple comparisons test or an unpaired Stu-
dent’s t-test was used with data represented as Mean ±
SD: * = p < 0.5, ** = p < 0.01, *** = p < 0.001, **** = p <
0.0001.
Results
The efficacy of systemic agonist anti-GITR antibody and
PD-1 blockade is enhanced by local peritumoral DR-BMC
administration
To assess if peritumoral administration of BMCs en-
hances the efficacy of systemically administered GITR
agonist and PD-1 blockade, the poorly immunogenic
lung cancer cell line, Line-1, was used. Checkpoint
blockade following TNFR agonists enhances tumor
clearance compared to simultaneous administration of
both antibodies [3], therefore, we administered GITR
agonist Ab first followed by PD-1 Ab blockade in
Line-1 tumor-bearing BALB/c mice (Fig. 1a). BMCs
were pulsed with the DRibbles vaccine derived from
Line-1 tumor cells before administration to provide
antigen and further activate APCs. Mice treated with
antibody therapy (anti-GITR and anti-PD-1 Abs) or
peritumoral DR-BMCs showed a modest delay in
tumor growth with a median survival of 31 and 33
days, respectively, compared to untreated mice
(median survival – 28 days). However, all mice suc-
cumbed to tumor outgrowth (Fig. 1b). In contrast,
mice treated with the tritherapy (anti-GITR, anti-PD-
1 and peritumoral BMCs) demonstrated the best effi-
cacy with tumor growth further delayed (median
survival of 41 days) and 19.3% complete tumor regres-
sion. Interestingly, the delayed survival in approxi-
mately 32% of the mice treated with tritherapy was
due to tumors that began to regress but ultimately
relapsed and continued to grow. Similar results were
seen when using the poorly immunogenic Panc02
pancreatic cancer model in C57BL/6 mice by which
33.3% of the tritherapy-treated mice were cured with
a median survival of 47 days, as compared to no cures
seen in the untreated (median survival – 32 days),
antibody treated (median survival – 41.5 days) or DR-
BMC treated mice (median survival – 42 days) (Fig.
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1c). Interestingly, administration of DR-BMCs earlier
during the antibody treatment regimen, at day 8 or
day 10, advanced median survival to 32 days com-
pared to 42 days seen when DR-BMCs were adminis-
tered at day 12 (Additional file 1: Figure S1). These
results demonstrated that peritumoral DR-BMC
administration enhanced the efficacy of systemically
administered GITR agonist and PD-1 blockade, espe-
cially when given delayed at day 12.
The necessity of each individual antibody with peritu-
moral DR-BMCs was assessed (Fig. 1d). No tumor
growth benefit was seen with PD-1 blockade and peritu-
moral DR-BMCs compared to untreated mice. Mice
receiving GITR agonist with peritumoral DR-BMCs or
PD-1 blockade showed delayed tumor growth kinetics
but no cures, suggesting an important yet insufficient
role of GITR agonist in generating a robust antitumor
response. However, tritherapy-receiving mice experi-
enced prolonged survival with a 20% cure rate. There-
fore, the combination of all three components, GITR
agonist, PD-1 blockade and peritumoral DR-BMCs, led
to delayed tumor growth and increased survival.
Peritumoral BMCs remain in the tumor for at least
2 weeks
Before peritumoral administration, BMCs expressed
varying levels of MHC II, CD11c and CD11b (Additional
file 1: Figure S2). Most cells expressed the DC marker,
CD24, and a small population expressed the macrophage
marker, F4/80. Very low Clec9a expression was detected
and only a small population of MHC II+ cells expressed
CD103 and IRF8, markers for cross-presenting DCs. A
substantial population (~ 20%) did express GR1, com-
monly found on neutrophils and MDSCs.
Previous reports show that intratumorally-injected DCs
labeled with a lipophilic dye trafficked to draining LNs
[29]. We assessed trafficking patterns of peritumorally-
injected DR-BMCs during tritherapy. DR-pulsed-BMCs
were labeled with a lipophilic dye (CellVue Claret or
PKH67) before peritumoral injections. Flow cytometry
analysis of tumors, LNs and spleens harvested 7 days after
DR-BMC administration demonstrated that the BMCs
remained in the tumor at this time point and were not de-
tected in the LN or spleen (Fig. 2a-b). A time-course study
showed live dye-labeled BMCs present in the tumor for at
least 14 days after peritumoral injections but still un-
detectable in the LNs or spleens (Fig. 2c). Injected BMCs
expressed similar levels of MHC II, CD11c and CD11b 7
days after peritumoral injections as they did before injec-
tions, with low or undetectable IRF8 and CD103 expres-
sion (Additional file 1: Figure S3), suggesting that the
lipophilic dye identified BMCs after tumor administration
and that the TME did not affect expression of these mole-
cules. Additionally, ~ 28% of the injected BMCs expressed
the LN homing receptor, CCR7, although BMCs were un-
detectable in the LNs by flow cytometry. Approximately
30% of the BMCs demonstrated proliferation by Ki-67 ex-
pression and approximately 40% of the BMCs expressed
the inhibitory molecule PD-L1. Therefore, peritumorally-
injected DR-BMCs remained locally within the tumor for
at least 2 weeks post administration and some were cap-
able of proliferating inside tumors.
Efficacy of Tritherapy depends on CD8+ and CD4+ T cells
To determine if a memory immune response was gen-
erated by the tritherapy, tritherapy-treated mice in
which Line-1 or Panc02 tumors completely regressed
were rechallenged with Line-1 or Panc02 tumor cells,
respectively, on the opposite flank. In the Line-1 model,
80% (4 out of 5) of the rechallenged mice remained
tumor-free whereas tumors grew out in all control mice
(Additional file 1: Figure S4A). The Line-1 rechallenged
mouse that did grow a tumor had delayed tumor kinet-
ics in which a palpable tumor was not detected until
20 days after rechallenge as opposed to 5–7 days seen in
the control mice. In the Panc02 model, 100% of the
rechallenged mice remained tumor-free (Additional file
1: Figure S4B).
The importance of T cells in tritherapy was deter-
mined by depleting CD8+ and/or CD4+ T cells before
starting tritherapy (Fig. 3a). CD8 or CD4 depletion
abrogated the tritherapy effects resulting in no mice
surviving past 50 days, similar to untreated or antibody-
therapy treated mice. Survival of mice depleted of both
CD8+ and CD4+ T cells was decreased even further.
Therefore, the tritherapy is dependent on both CD8+
and CD4+ T cells.
Tritherapy alters the CD4+ T-cell compartment within the
TME
We next assessed the effect of tritherapy on tumor T-
cell infiltration. Antibody therapy increased CD8+ T-cell
infiltration into tumors similar to tritherapy-treated mice
(Fig. 3b). When assessing tumor-specific T cells, all
(See figure on previous page.)
Fig. 1 Peritumoral BMC vaccination enhances the survival of GITR agonist and PD-1 blockade treated tumor-bearing mice. a, Experimental
schematic. b, Line-1-tumor bearing mice individual tumor growth curves and overall survival. Pooled data from 5 independent experiments are
shown. c, Panc02-tumor bearing mice individual tumor growth curves and overall survival. Pooled data from 2 independent experiments are
shown. d, Line-1 tumor bearing mice individual tumor growth curves and overall survival. Representative data from 2 independent experiments
are shown (n = 5)
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Fig. 2 Peritumorally injected BMCs remain in the tumor of tritherapy-treated mice. a, Treated mice were euthanized 7 days after peritumoral
injection of PKH67-labeled BMCs. Representative dot plots of PKH67-labeled cells from tumors of one experiment (n = 5) are shown. b, PKH67-
labeled cells in the tumor, LN or spleen of mice 7 days after peritumoral vaccination of PKH67-labeled BMCs. Representative data (mean ± SD) of
5 mice in the antibody and tritherapy group and of 4 mice in the untreated and BMC only group from one independent experiment is shown. c,
(Top row) Percent of CellVue+ cells found in the tumors, LNs and spleens of antibody treated mice injected with or without peritumoral CellVue-
labeled BMCs 1, 3, 7 or 14 days after peritumoral BMC vaccination. Data represents the mean ± SEM of 3 mice in the tritherapy group and
mean ± SEM of 2 mice in the antibody therapy group from one experiment. (Bottom row) Percent of PKH67+ cells found in the tumors, LNs and
spleens of antibody treated mice injected with or without peritumoral PKH67-labeled BMC 1, 3, 7 or 10 days after peritumoral BMC vaccination.
The data represents the mean ± SEM of 3 mice in the antibody and tritherapy group and 5 mice in the untreated group on days 1,3, and 10
whereas on day 7, mean ± SEM of 4 mice for each group is displayed from one experiment
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therapies trended towards increased similar levels of
tumor-infiltrated AH1-specific CD8+ T cells, which have
led to protective antitumor responses in many BALB/c
originating tumors [30, 31]. In the immunogenic
Panc02-SIY tumor model, antibody therapy increased
SIY-specific CD8+ T cells but the addition of peritu-
moral DR-BMCs did not further augment the therapy
(Fig. 3b). Therefore, the percent of tumor infiltrating
CD8+ T cells was unaffected by peritumoral DR-BMC
inclusion compared to antibody therapy alone, suggest-
ing the absence of cross-presentation by peritumorally
administered BMCs.
The percentages of total tumor-infiltrating CD4+ T
cells (Fig. 3c) also did not vary among the different treat-
ment groups. However, further analysis showed in-
creased Tbet+CD4+ Th1 cells and FoxP3-CD4+ effector
T-cells (Teff) with decreased FoxP3 + CD4+ regulatory
T-cells (Tregs) in tritherapy-treated tumors compared to
all other groups (Fig. 3c), suggesting TME skewing to-
wards antitumor immunity. Subsequently, antibody ther-
apy increased the CD8+ T-cell:Treg ratio in the tumor
without further augmentation from peritumorally ad-
ministered DR-BMCs, but tritherapy significantly in-
creased the ratio of tumor CD4+ Teffs:Tregs compared
to all other groups (Fig. 3d). Similar trends were also
seen in the Panc02 model (Additional file 1: Figure
S5A). Therefore, GITR agonist and PD-1 blockade mod-
estly increased the percentage of CD8+ T cells in the
tumor and the addition of peritumoral DR-BMCs
skewed the tumor CD4+ T-cell compartment towards
an immune-stimulating response.
Tritherapy leads to increased proliferation of CD4+ Teff
cells in the tumor
Due to the variations in CD4+ Teffs and Tregs in
tritherapy-treated tumors, we assessed the effect of peri-
tumoral DR-BMCs on T-cell proliferation. Antibody
therapy increased CD4+ T-cell (both Teff and Tregs)
proliferation compared to untreated mice, however only
tumor CD4+ Teffs and not Tregs proliferated even fur-
ther with tritherapy (Fig. 3e). This increased CD4+ Teff
cell proliferation was also seen in the Panc02 tumor
model (Additional file 1: Figure S5B) and explains the al-
tered Teff to Treg ratio by the tritherapy.
Tritherapy increases functional T cells in the tumor
CD4+ T cells provide help to CD8+ T cells to increase
their effector function [32]. Since tritherapy increased
CD4+ Teffs, we next assessed the cytolytic ability of
CD8+ T cells post tritherapy (Fig. 4a-b). Antibody ther-
apy trended towards increased expression of granzyme
A (GzA) and the degranulation marker, CD107a, on
tumor CD8+ T cells compared to untreated mice, how-
ever a significant difference was not detected. Interest-
ingly, tritherapy significantly enhanced GzA+, CD107a +
and GzA + CD107a + CD8+ T cells (Fig. 4b). Low GzA
and CD107a expression was detected in tumor CD4+ T
cells with no significant differences between the groups
(Additional file 1: Figure S6A). Consequently, although
tritherapy did not alter CD8+ T cell tumor percentages,
these cells exhibited a more cytolytic phenotype. Expres-
sion of T-cell activation markers, CD69, ICOS and
TIGIT, on tumor-infiltrating T-cells was not affected
(Additional file 1: Figure S6B).
Next, T-cell functional capacity was assessed by de-
tecting in situ cytokine production 4.5 h after intraven-
ous BFA administration. Cytokine production by tumor
CD8+ T cells was not significantly different between
groups (Fig. 4c). In contrast, while antibody therapy only
modestly increased IFN-γ-producing CD4+ T cells in
the tumor, tritherapy significantly increased IFN-γ+,
TNF-α + and IFN-γ + TNF-α + CD4+ T cells compared
to all other treatments (Fig. 4d-e). Taken together, these
results suggest that tritherapy increases CD8+ T-cell
cytolytic activity and enhances CD4+ T-cell cytokine
production in the tumor.
To determine if tritherapy increased tumor-specific
CD4+ T cells in the tumor, we used BALB/c Nur77GFP
reporter mice. Nur77 is specifically upregulated early
after T cell receptor (TCR) engagement and not as a re-
sult of inflammation [33], therefore it is a surrogate
marker for antigen-specific stimulation. Mice receiving
tritherapy had increased Nur77 expression on CD4+ T
cells compared to untreated or antibody therapy-treated
(See figure on previous page.)
Fig. 3 CD8+ and CD4+ T cells are required for tritherapy efficacy. a, Tritherapy-treated mice were depleted of CD4+ and/or CD8+ cells 1 day
before beginning anti-GITR antibody administration. Survival was assessed. Pooled data from 2 independent experiments is shown. b, Tumors
from line-1-tumor bearing mice were harvested 7 days after p.t. DR-BMC injections and analyzed by flow cytometry for total CD8+ T-cell (left) and
AH1-tetramer-specific CD8+ T-cell (middle) infiltration into the tumor. Tumors from Panc02-SIY tumor bearing mice were harvested 10 days after
p.t. DC vaccination and analyzed by flow cytometry for SIY-specific CD8+ T cells (right). Line-1 tumor CD8+ T-cell data demonstrates pooled data
from 6 independent experiments whereas mean ± SEM from one independent experiment each is shown for AH1 + CD8+ T cells (n = 4) and
pSIY+CD8+ T cells (n = 3). c, Same experimental setup as b, but Line-1 tumor CD4+ T cells were assessed. Pooled data from 6 independent
experiments is shown for total CD4+ T cells, from 2 independent experiments for Tbet+CD4+ Th1 cells, and from 4 independent experiments for
CD4+ Teffs and Tregs. d, Same experimental setup as c, but the ratios of CD8+ T cells:Tregs and CD4+ Teffs:Tregs in the tumor were assessed.
Pooled data from 5 independent experiments is shown. e, Same experimental setup as c-d, but intracellular Ki-67 staining was assessed in tumors
by flow cytometry. Pooled data from 3 independent experiments is shown. b-e One-Way ANOVA
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mice (Additional File 1: Figure S6C). No significant dif-
ferences in Nur77 + CD8+ T cells were detected, similar
to results obtained when assessing AH1 or SIY-specific
CD8+ T cells (Fig. 3b). These results suggest that peritu-
moral administration of DR-BMCs increases tumor-
reactive CD4+ T cells in the tumor. Also, antibody ther-
apy trended towards increased TCRβ clonality within tu-
mors, however no significant differences were detected
(Additional File 1: Figure S6D). Therefore, antibody
therapy led to overall T cell enrichment within the
tumor but no additional change was seen with DR-BMC
administration.
Increased T-cell activation in tumor draining LNs of
tritherapy-treated mice
Tumor-specific T cell priming occurs in tumor drain-
ing LNs [34], therefore we assessed T-cell activation,
function and proliferation in the LNs of treated mice.
Similar percentages of CD8+ T cells and CD4+ Teffs
were detected between groups in the LNs, however a
slight decrease in total CD4+ T cells and Tregs was
seen in tritherapy-treated mice (Fig. 5a). In contrast,
similar T-cell percentages were seen in the spleens ex-
cept that antibody therapy alone increased splenic
Tregs (Additional file 1: Figure S7A).
The addition of peritumoral DR-BMCs to systemic
antibody therapy led to increased ICOS and CD69 ex-
pression on both CD8+ (Fig. 5b) and CD4+ T cells (Fig.
5c) within LNs. TIGIT expression remained unaffected.
ICOS is highly expressed on Tregs, therefore we further
investigated effects on CD4+ T-cell subtypes. Antibody
therapy increased ICOS and TIGIT expression on
Tregs, however only tritherapy-treated mice had in-
creased ICOS expression on CD4+ Teff cells in the LNs
(Fig. 5d). Additionally, cytolytic activity (GzA and
CD107a expression) was dramatically enhanced on
CD8+ T cells within LNs of tritherapy-treated mice
(Fig. 5e). Conversely, in the spleen, antibody therapy in-
creased CD4+ T-cell activation whereas peritumoral
DR-BMC inclusion did not further augment this effect
(Additional file 1: Figure S7B). These results suggest
that outside the tumor, systemic GITR agonist and PD-
1 blockade increases peripheral T-cell activation in the
spleen and LN, whereas the inclusion of peritumoral
DR-BMC administration further augments the activa-
tion of CD8+ T cells and CD4+ Teffs only in tumor-
draining LNs.
Peritumoral DR-BMC administration promotes tumor
rejection locally within the TME
Given the increased effector T-cell activity seen in the
tumor as well as the LNs of tritherapy-treated mice, we
next assessed if the LN T-cell activation was necessary
for tumor rejection. For these studies, we injected the
drug FTY720, a S1P1R agonist that prevents T-cell
egress from secondary lymphoid structures, daily either
starting before tumor inoculation or 1 day before peritu-
moral BMC administration. Mice that received FTY720,
had decreased blood T-cell circulation during treatment
(Additional file 1: Figure S8). When FTY720 was started
before tumor inoculation, all tumors grew out with simi-
lar rapid kinetics (Fig. 6a), suggesting that the LNs were
important for initial T-cell priming.
However, the delayed tumor growth curve seen with
tritherapy was unaffected by FTY720 administration start-
ing 1 day before peritumoral BMC administration, in
which tumor regression was seen in 6.7% of mice (Fig.
6b). No difference in tumor growth was seen with anti-
body therapy given with or without FTY720, suggesting
that the drug itself did not affect tumor growth. Moreover,
tritherapy-treated mice with or without FTY720 treatment
before peritumoral BMC administration showed similar
increases in CD4+ Teff:Treg ratios and cytolytic CD8+ T
cells in the tumors (Fig. 6c), as well as increased T-cell ac-
tivation and cytolytic CD8+ T cells within the LNs (Fig.
6d). Overall, these results suggest that although T-cell ac-
tivation was seen in LNs of tritherapy-treated mice, tumor
rejection induced upon peritumoral DR-BMC administra-
tion was locally induced within the tumor and independ-
ent of T-cell recruitment from the LNs. However, an
initial T cell priming event within the LNs before begin-
ning antibody therapy was required in order for the peri-
tumoral DR-BMCs to augment the effector function of
the primed T cells.
Peritumoral cross-presenting DC administration delays
survival of antibody therapy-treated mice
Increased abundance of intratumoral cross-presenting
DCs correlates with improved overall survival [35] by
(See figure on previous page.)
Fig. 4 Increased effector function of CD8+ and CD4+ T cells in tumors of tritherapy-treated mice. a, Representative flow plots and b, graphical
representation of intracellular GzA and surface CD107a expression on CD8+ T cells in tumors harvested 7 days after p.t. DR-BMC injections. Pooled
data from 3 independent experiments is shown for GzA + CD8+ T cells, and from 2 independent experiments for CD107a + and GzA + CD107a +
CD8+ T cells. One-Way ANOVA. c, 10 days after DR-BMC p.t. injections, Line-1 tumors were harvested 4.5 h after BFA i.v. injections and intracellular
cytokine staining on CD8+ T-cells was performed. Data shown here is representative of 2 independent experiments. d, Same as c but
representative flow plots of tumor-infiltrating CD4+ T cells. e, Same as c-d but cytokine production by tumor CD4+ T cells is shown. Data shown
here is representative of 2 independent experiments. One-Way ANOVA
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attracting [36], stimulating and expanding tumor-
specific T cells [37]. These DCs are characterized by
CD103 and Clec9a expression in mice. DRibbles express
Clec9a ligands aiding in cross-presentation [21]. BMCs
contain very low levels of CD103+ DCs and the presence
of these DCs within the TME are sparse [37, 38]. There-
fore, we assessed the administration of CD103+ DCs
peritumorally with antibody therapy.
Generation of cross-presenting DCs from bone mar-
row cells led to ~ 57% MHC II + CD11c + DCs in cul-
ture with 74.7% expressing CD103 and only 23.1%
expressing CD11b (Additional file 1: Figure S9A).
Clec9a was expressed on 32.4% of the DCs and very
few cells expressed MDSC (CD11b + GR1+) or macro-
phage (CD24-F4/80+) markers. Upon peritumoral DR-
DC injections with antibody therapy (DR-DC-trither-
apy), 20% of tumors regressed, similar to mice receiving
DR-BMC-tritherapy. DR-DC-tritherapy mice showed
marginal delays in tumor growth with a median survival
of 46 days as compared to 37.5 days seen with DR-
BMC-tritherapy (Additional file 1: Figure S9B). In
addition, the injected DCs remained in the tumors and
were not detected in LNs or spleens (Additional file 1:
Figure S9C) similar to that seen with BMCs, suggesting
that the injected DCs also orchestrate the local immune
stimulation occurring within tumors.
Antigen presentation in situ is not required by
peritumoral DR-BMC/DC administration for tritherapy
efficacy
DRibbles contain tumor antigens and activate an in-
nate inflammatory response [21, 25]. We assessed if
DRibbles could replace DRibbles-pulsed-BMCs in the
tritherapy. DR-tritherapy led to enhanced survival in
both the Line-1 and Panc02 tumor models compared
to antibody therapy alone (Fig. 7a-b). Mice in the
Line-1 tumor model were not cured unlike those
treated with DR-BMC-tritherapy or DR-DC-tritherapy.
In the Panc02 tumor model, DR-tritherapy-treated
mice showed similar cure rates compared to those re-
ceiving DR-BMC-tritherapy (Fig. 7c).
Pulsing BMCs with DRibbles increased IL-1β, IL-6, IL-
12p40 and Type I IFN production compared to unpulsed
BMCs (Fig. 7c). Therefore, besides providing antigen,
DRibbles can generate an innate inflammatory response.
We previously saw better tritherapy efficacy when DR-
BMCs were administered later at day 12 after T-cell
priming had most likely already occurred (Additional file
1: Figure S1). Therefore, the necessity of T-cell priming
by the transferred BMCs/DCs was assessed by using
allogeneic BMCs/DCs containing mismatched MHC
molecules thus rendering them unable to present anti-
gen to host T cells. Mice receiving tritherapy with allo-
genic DR-pulsed-BMCs/DCs led to a similar increase in
survival as mice receiving tritherapy with syngeneic DR-
pulsed-BMCs/DCs (Fig. 7d-e). These results suggest that
peritumorally administered DR-pulsed-APCs do not
need to present antigens in situ for tritherapy efficacy
and that perhaps a generated inflammatory response
could be responsible for the enhanced tumor regression.
Discussion
In this present study, the efficacy of systemically admin-
istered GITR agonist and PD-1 blockade was augmented
by peritumoral DR-pulsed-BMC/DC administration in-
dependently of antigen presentation and through local
alterations of T-cell effector functions within the tumor.
Herein, we found that peritumorally-administered
BMCs/DCs remained within the tumor and did not mi-
grate to LNs as is expected of activated DCs. FTY720
studies suggested that tumor regression in tritherapy-
treated mice was induced by a local influence of the
peritumoral DR-BMCs on T cells within the tumor and
did not require the effects of the LN even though robust
T-cell activation was detected in LNs. In addition, DR-
BMCs administered a week after beginning antibody
therapy led to better antitumor responses compared to
earlier administration, and the use of MHC-mismatched
APCs in the tritherapy led to similar results as MHC-
matched APCs. Together, these results demonstrate that
antigen presentation by peritumorally-injected-BMCs is
not necessary for tritherapy efficacy. Despite this, the in-
clusion of intratumoral DRibbles-pulsed APCs to anti-
body therapy promoted the further expansion and
differentiation into Teff cells and heightened the cyto-
lytic potential of CD8+ T cells in the tumor.
Pulsing BMCs with DRibbles increased the in vitro
production of pro-inflammatory cytokines IL-6, IL-1β,
IL-12 and Type I IFNs and replacing DR-pulsed-BMCs
with DRibbles also delayed tumor growth kinetics, albeit
not as prominently. These results suggest that a local in-
flammatory response mediated by DRibbles pulsing
(See figure on previous page.)
Fig. 5 Increased T cell activation in lymph nodes of tritherapy-treated mice. a, LNs were harvested and analyzed by flow cytometry 7 days after
p.t. DR-BMC administration. Pooled data from 2 independent experiments are shown here. b, Same as a but activation markers on CD8+ T cells
and c, CD4+ T cells were analyzed. Shown is representative data of 4 independent experiments for ICOS expression, 2 independent experiments
for CD69 expression and one experiment for TIGIT expression. d, Same as a-c, but activation markers on effector FoxP3-CD4+ T cells versus
FoxP3 + CD4+ Tregs are shown. Representative data from 2 independent experiments are shown. e, Same as a-d, but cytolytic potential of CD8+
T cells from the lymph nodes are shown. Pooled data from 2 independent experiments are shown. b-e One-Way ANOVA
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could lead to the sustained antitumor effects seen. In-
flammatory cytokines, such as IL-12 and Type I IFNs,
have shown to increase proliferation, adhesion and costi-
mulatory molecule expression, activation, effector func-
tion of effector and memory T cells, [39] and to lower
TCR antigen sensitivity required for activation [40]. In
addition, the inflammatory cytokine milieu can also ef-
fect T-cell recruitment by altering sensitivity towards
selectins [39], increasing tumor vasculature as evidenced
by increased IL-6 production [41] and by inducing T-
cell chemoattractants such as CCL5 and CXCL9 [42,
43]. Intratumoral administration of oncolytic viruses that
promoted inflammatory cytokine production, in particu-
lar Type I IFNs, have also led to similar enhancements
of systemic CTLA-4 blockade in which antitumor T-cell
responses in distant tumors were also seen [44]. There-
fore, altering the inflammatory cytokine milieu can posi-
tively impact local effector and memory T cells and
sustain T-cell immunity within the tumor.
Since antigen presentation by peritumorally-transferred-
DR-APCs was not required and mice receiving DRibbles-
tritherapy demonstrated enhanced survival, it is possible
that administrating DAMPs alone that initiate an innate
inflammatory response may be sufficient to enhance the
effects of antibody therapy. Future studies identifying the
necessity of individual inflammatory mediators or DAMPs
sufficient to enhance the effects of antibody therapy will
prove beneficial. However, considering the vast number of
inflammatory mediators activated by DRibbles, it is highly
possible that a combination of many DAMPs will be re-
quired to mediate the same antitumor effects seen with
DRibbles.
Previous studies using GITR agonist and PD-1 block-
ade show marginal synergy between the two antibodies
with minimal tumor clearance, therefore, combination
with chemotherapy, vaccination or radiation to further
prime an immune response was assessed to increase
tumor clearance [2, 4, 16]. These studies differ from ours
in which peritumorally-administered DR-BMCs were
used to safely manipulate the T-cell response generated
previously by antibody therapy and not to necessarily
prime more T-cells. A similar study demonstrated that
intratumoral or systemic GITR agonist antibody com-
bined with intratumoral administration of DCs and
CD4+ T cells led to enhanced survival compared to
subcutaneous DCs and intravenous CD4+ T cells [20].
The authors attributed intratumoral delivery with in-
creased antitumor and decreased pro-tumor cytokines/
chemokines within the TME which in turn increased the
tumor influx of CD8+ T cells, also suggestive of how lo-
cally modulating the inflammatory milieu, in this case
with tumor lysate-pulsed DCs, can recruit T-cells to the
tumor. Consequently, intra/peritumoral DC administra-
tions are more beneficial than the traditional subcutane-
ous administration route in modulating the TME locally
towards an antitumor environment and could potentially
be combined with many different agents that previously
prime T-cell immunity but are insufficient in leading to
tumor regression. Given that DC-tritherapy led to simi-
lar results as BMC-tritherapy, a clinically relevant and
safe approach would be to isolate natural circulating
DCs or monocytes from patient peripheral blood mono-
nuclear cells (PBMCs) via apheresis. Since APC antigen
presentation was not required, allogeneic DCs could also
be used.
Previous studies demonstrate that cross-presenting
DC presence within the TME suggests better synergy
with T-cell targeted therapies. Early i.p. Flt3L and intra-
tumoral polyIC administrations synergized with PD-L1
blockade [38] or TNFR CD137 agonist and PD-1 block-
ade combination therapy [45] through the expansion of
CD103+ DCs within the TME. These studies suggested
that tumor-resident cross-presenting DCs were import-
ant for T-cell tumor infiltration allowing for further
manipulation by T-cell targeted therapies. In our study,
BMCs had very low levels of CD103 or IRF8, and major
manipulations of CD8+ T cells within the TME were
not detected, suggesting that the majority of BMCs
were not cross-presenting DCs. Interestingly, peritu-
moral injections of higher percentages of cross-
presenting DCs expressing CD103 and CLEC9A did
not significantly improve cure rates when used in the
tritherapy, although delayed median survival was seen.
Consistent with our data showing that antigen presen-
tation by the injected APCs was not necessary for
tritherapy efficacy, a recent study highlights the ability
of Batf3-dependent-DCs to lead to tumor rejection by
methods other than cross-presentation [46], which may
play a role in the tritherapy. Therefore, we predict that
peritumorally-administered DR-BMCs/DCs did not
(See figure on previous page.)
Fig. 6 Tritherapy promotes tumor regression locally within the TME after initial lymph node T cell priming. a, Individual tumor growth curves and
survival of antibody therapy and tritherapy-treated mice with and without daily FTY720 administered starting at day 0 before tumor inoculation.
Shown is data from one independent experiment (n = 5). b, Individual tumor growth curves and survival of antibody therapy and tritherapy-
treated mice with and without daily FTY720 administered starting 1 day before p.t. DR-BMC vaccination. Pooled data from 3 independent
experiments are shown. c, Mice were treated as in b but sacrificed 7 days after peritumoral BMC vaccination. Line-1 tumors were harvested and
analyzed by flow cytometry. d, Mice were treated as in b-c but LNs were harvested and analyzed by flow cytometry. c-d data shown is mean ±
SD of one experiment with n = 5. One-Way ANOVA
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increase tumor T-cell infiltration or priming, but ma-
nipulated the local immune TME that was previously
established by GITR agonist treatment, perhaps
through an antitumor inflammatory response involving
cytokine/chemokine production by the DRibbles-
activated APCs.
Tritherapy led to increased survival of mice with 20%
cures compared to antibody therapy alone, in which all
mice succumbed to tumor burden. However, many tu-
mors began to regress with tritherapy but would then
progress about a week after BMC/DC administration,
whereas some were completely refractory to treatment,
analogous to what is seen in patients. Live injected
BMCs/DCs remained within the tumor for at least
2 weeks after peritumoral administration and multiple
follow up peritumoral DR-BMC administrations did not
improve efficacy (data not shown), suggesting that the
cells are still present and viable to exert effects even
when some tumors begin to progress. Additionally, peri-
tumorally administered IL-2 or IL-15 did not further po-
tentiate tritherapy efficacy (data not shown). It is
possible that tumor escape mechanisms could be at play
in which tumor cells may lose neoantigens or pursue im-
mune evasion tactics. Also, GITR agonist therapy alone
may not generate enough tumor-specific T-cells thus,
the addition of early vaccination or radiation to expand
tumor-specific T cells may provide benefit to the ther-
apy. Another possibility is that despite PD-1 blockade,
prolonged exposure of T cells to the TME could lead to
dysfunction/exhaustion thus allowing tumors to progress
after an initial regression. Therefore, additional check-
point inhibitors, such as CTLA-4, TIM-3, LAG-3, etc.,
could be assessed in combination.
Conclusions
DC vaccines administered systemically in the clinic failed
in leading to tumor regression [47, 48], however peritu-
moral administration may prove more beneficial. We
report that peritumoral administration of DRibbles-
pulsed-APCs can enhance the efficacy of systemic T-
cell-targeted immunotherapies by locally manipulating
the TME. Enhanced efficacy was seen even in the
absence of antigen presentation and perhaps through
local innate inflammatory modulations mediated by
DRibbles-pulsed-APCs, thus creating a supportive envir-
onment in which T-cell immunity is sustained.
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